All In Biotech

Drug Trial Radar · NCT02102022

Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced GI Malignancies Focusing on Hepatocellular Carcinoma

Phase 1/2 Study of ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Apr 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

140

Actual

Start

Nov 2014

Primary completion

Feb 2020

Study completion Feb 2020

Sponsor

Lead sponsor
Polaris GroupIndustry
Sponsor type
Industry
First posted
Apr 2, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1: Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies. Phase 2: Assessment of the objective response rate (ORR), measured by RECIST 1.1 criteria as assessed by blinded independent central review (BICR).

Conditions

  • Advanced Gastrointestinal (GI) Malignancies
  • Hepatocellular Carcinoma
  • Gastric Cancer
  • Colorectal Cancer

Interventions

  • ADI-PEG 20 plus modified FOLFOX6Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Date of first study drug administration to the date of disease progression (measured every 8 weeks) or death (whichever occurs first), up to 24 months

Locations

35 sites in 6 countries. Site status is shown where the registry gives one.

  • California Pacific Medical Center

    San Francisco, California

  • Emory University

    Atlanta, Georgia

  • The University of Chicago Medical Center

    Chicago, Illinois

  • The University of Kansas Cancer Center

    Westwood, Kansas

  • Masonic Cancer Center

    Minneapolis, Minnesota

  • Washington University

    St Louis, Missouri

  • Memorial Sloan-Kettering Cancer Center

    New York, New York

  • Oregon Health and Science University

    Portland, Oregon

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • University of Washington

    Seattle, Washington

  • The Chinese People's Liberation Army 81 Hospital

    Nanjing, Jiangsu, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

  • National Cancer Institute of Napoli IRCCS G. Pascale

    Naples, Italy

  • IRCCS Ca Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy

  • Pusan National University Hospital

    Busan, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • The Catholic University of Korea, Seoul ST. Mary's Hospital

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, Gyeonggi-do, South Korea

  • Changhua Christian Hospital

    Changhua, Taiwan

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan

  • Chang Gung Medical Foundation - Kaohsiung

    Kaohsiung City, Taiwan

  • National Cheng Kung University Hospital

    Tainan, Taiwan

  • Chi Mei Medical Center

    Tainan, Taiwan

  • Chi Mei Hospital, Liouying

    Tainan, Taiwan

  • Mackay Memorial Hospital

    Taipei, Taiwan

  • Taipei Medical University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Tri-Service General Hospital

    Taipei, Taiwan

  • Chang Gung Medical Foundation - Linkou

    Taoyuan, Taiwan

  • Royal Free Hospital

    London, United Kingdom

  • Guy's & St Thomas' NHS Foundation Trust

    London, United Kingdom

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • The Clatterbridge Cancer Centre NHS Foundation Trust

    Bebington, Wirral, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.